Immunosuppressive therapy of ocular inflammatory diseases.
D000293:Adolescent; D000328:Adult; D001528:Behcet Syndrome / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D002648:Child; D016039:Corneal Transplantation; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D009877:Endophthalmitis / Q000188:drug therapy*; D005128:Eye Diseases / Q000188:drug therapy; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced; D007109:Immunity; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009879:Ophthalmia, Sympathetic / Q000188:drug therapy; D009915:Orbit; D011024:Pneumonia, Viral / Q000139:chemically induced; D014181:Transplantation Immunology / Q000187:drug effects; D014606:Uveitis, Anterior / Q000188:drug therapy
D003520:Cyclophosphamide; D008727:Methotrexate